Siemens’ Varian Wins FDA Nod for Low-Dose OA Radiotherapy

Siemens Healthineers announced that its Varian TrueBeam radiotherapy systems (TrueBeam, TrueBeam STx, VitalBeam, and Edge) obtained U.S. Food and Drug Administration (FDA) 510(k) clearance for use of low-dose radiation therapy (LDRT) in adults with medically refractive osteoarthritis (OA).

The system merges high-resolution imaging with accurate dose control so clinicians can offer personalized care with precision, while keeping the same workflows they trust for cancer care. The clearance grows Varian’s radiotherapy systems over cancer care into chronic musculoskeletal conditions to bring radiotherapy to people living with persistent pain and limited mobility.

The newly cleared indication provides a non-invasive, outpatient treatment option that’s based on a growing evidence body showing that LDRT can target inflammation at the source, reduce pain, improve joint function, and delay the necessity for surgical intervention.

“This clearance is a powerful example of how we’re expanding the reach of precision radiotherapy to meet broader healthcare needs,” said Arthur Kaindl, head of Varian. “At Siemens Healthineers, we’re uniquely positioned to lead this transformation by bringing imaging and therapy together to improve lives not just in cancer care, but now in chronic conditions like osteoarthritis.”

The FDA nod builds on the company’s list of approvals in non-oncological indications, including radiosurgery treatment for medically refractory essential tremor in adults.